Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Percheron Therapeutics ( (AU:PER) ) has provided an announcement.
Percheron Therapeutics reported positive clinical and preclinical data for its drug HMBD-002, showing a favorable safety profile and potential efficacy in treating various cancers. The company is advancing to a phase II clinical trial and has completed the transfer of the IND application with the FDA, positioning HMBD-002 for further development. Additionally, Percheron received a significant R&D tax rebate and appointed two senior executives to support the drug’s progress.
The most recent analyst rating on (AU:PER) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on Percheron Therapeutics stock, see the AU:PER Stock Forecast page.
More about Percheron Therapeutics
Percheron Therapeutics Limited is an international biotechnology company focused on developing novel therapies for oncology and rare diseases.
Average Trading Volume: 2,975,046
Technical Sentiment Signal: Sell
Current Market Cap: A$8.7M
For a thorough assessment of PER stock, go to TipRanks’ Stock Analysis page.